Chinese Regulator Approves DAXXIFY for Registration
The National Medical Products Administration has approved for registration, DAXXIFY, a botulinum toxin type A for injection, used to temporary improve the appearance of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in adult patients, a Monday filing with the Hong Kong Exchange said.
Sisram Medical's (HKG:1696) subsidiary was given the sub-license of the product by Shanghai Fosun Pharmaceutical Industrial Development for the rights to use, import, sell, and commercialize in the region.
The original licensor, the US-based Revance Therapeutics, is the right holder of the product in the region.
The company's shares were down 7% on Monday's close.
Price (HKD): $3.19, Change: $-0.24, Percent Change: -7.00%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。